Antitumor effect of K18 on metastatic models.
K18 is a newly synthesized antitumor agent which is the conjugate form of human immunoglobulin with p-di (2-chloroethyl)-amino-L-phenylalamine (melphalan). The antitumor effect of K18 on two animal metastatic models was investigated: (a) Lewis lung carcinoma was transplanted into thigh muscle of mice, followed by the reaction of the primary lesion, or the tumor was transplanted through the tail vein: (b) a renal model was also created, where colon-26 was inoculated into the renal capsule of BALB/c mice. Oral administration of K18 resulted in the decrease in the number of nodules in the lung in the case of tumor transplantation through tail vein.
Fujii
T
T
Biomedical Research Laboratories, Kureha Chemical Industry Co., Ltd., Tokyo, Japan.
Furusho
T
T
Niimura
K
K
Sugita
N
N
Oguchi
Y
Y
Matsunaga
K
K
Saito
K
K
Kobayashi
Y
Y
Iijima
H
H
Fujii
M
M
D000818:Animals; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007136:Immunoglobulins; D000922:Immunotoxins / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000556:secondary*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D008558:Melphalan / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D009362:Neoplasm Metastasis; D005719:gamma-Globulins / Q000627:therapeutic use*
D007136:Immunoglobulins; D000922:Immunotoxins; C045927:K-18 conjugate; D005719:gamma-Globulins; D008558:Melphalan